LPGO Share Price Performance
SEK 0.18
-0.15 (-44.87%)
Price SEK 0.18
Share PriceSEK 0.18
LPGO Community Narratives
There are no narratives available yet.
Recent LPGO News & Updates
No updates
Lipigon Pharmaceuticals AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.18
- Gross Margin
- -182.58%
- Net Profit Margin
- -262.48%
- Debt/Equity Ratio
- 0%
Lipigon Pharmaceuticals AB (publ) Competitors
About LPGO
- Founded
- 2010
- Employees
- 7
- CEO
- WebsiteView website
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden.
Swedish Market Performance
- 7 Days: -1.5%
- 3 Months: 2.8%
- 1 Year: 1.4%
- Year to Date: -0.4%
Over the last 7 days, the market has dropped 1.5%, driven by a decline of 2.3% in the Industrials sector. Although the market performance has been flat over the past year. Earnings are forecast to grow by 17% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading